drugset / Trial / NCT06355024
Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.
Timeline
- Start
- 2024-05-11
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inosine | Unknown | 200 mg | Oral |
| Background | Capecitabine | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Eribulin | Small molecule | — | — |
| Background | UTD1 | Unknown | — | — |
| Background | Vinorelbine | Small molecule | — | — |